1. Home
  2. ETJ vs KROS Comparison

ETJ vs KROS Comparison

Compare ETJ & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ETJ
  • KROS
  • Stock Information
  • Founded
  • ETJ 2007
  • KROS 2015
  • Country
  • ETJ United States
  • KROS United States
  • Employees
  • ETJ N/A
  • KROS N/A
  • Industry
  • ETJ Finance Companies
  • KROS Biotechnology: Pharmaceutical Preparations
  • Sector
  • ETJ Finance
  • KROS Health Care
  • Exchange
  • ETJ Nasdaq
  • KROS Nasdaq
  • Market Cap
  • ETJ 578.8M
  • KROS 558.9M
  • IPO Year
  • ETJ N/A
  • KROS 2020
  • Fundamental
  • Price
  • ETJ $9.06
  • KROS $14.17
  • Analyst Decision
  • ETJ
  • KROS Buy
  • Analyst Count
  • ETJ 0
  • KROS 13
  • Target Price
  • ETJ N/A
  • KROS $20.63
  • AVG Volume (30 Days)
  • ETJ 175.6K
  • KROS 601.6K
  • Earning Date
  • ETJ 01-01-0001
  • KROS 08-06-2025
  • Dividend Yield
  • ETJ 8.30%
  • KROS N/A
  • EPS Growth
  • ETJ N/A
  • KROS N/A
  • EPS
  • ETJ N/A
  • KROS 0.11
  • Revenue
  • ETJ N/A
  • KROS $214,713,000.00
  • Revenue This Year
  • ETJ N/A
  • KROS $5,006.76
  • Revenue Next Year
  • ETJ N/A
  • KROS N/A
  • P/E Ratio
  • ETJ N/A
  • KROS $127.57
  • Revenue Growth
  • ETJ N/A
  • KROS 91657.70
  • 52 Week Low
  • ETJ $7.20
  • KROS $9.12
  • 52 Week High
  • ETJ $8.47
  • KROS $72.37
  • Technical
  • Relative Strength Index (RSI)
  • ETJ 63.12
  • KROS 59.31
  • Support Level
  • ETJ $8.60
  • KROS $13.26
  • Resistance Level
  • ETJ $9.07
  • KROS $13.77
  • Average True Range (ATR)
  • ETJ 0.09
  • KROS 0.37
  • MACD
  • ETJ 0.01
  • KROS 0.05
  • Stochastic Oscillator
  • ETJ 94.35
  • KROS 92.54

About ETJ Eaton Vance Risk-Managed Diversified Equity Income Fund of Beneficial Interest

Eaton Vance Risk-Managed Diversified Equity Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to provide current income and gains, with a secondary objective of capital appreciation. The group invests in various sectors such as financials, healthcare, consumer discretionary, consumer staples, industrials, energy, utilities, telecommunication services, and materials. Under normal market conditions, the Fund's investment program consists of majorly owning a diversified portfolio of common stocks and employing a variety of options strategies.

About KROS Keros Therapeutics Inc.

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Share on Social Networks: